Skip to main content
SleepCited

Kava pour Troubles du Sommeil Liés à l'Anxiété

A

Based on 23 studies (4 meta-analyses, 1 RCT) with 2,043 total participants. Results are mixed across studies.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'ingredient\u003Dkava\u0026condition\u003Danxiety\u002Drelated\u002Dsleep'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

En conclusion

Based on 23 studies (4 meta-analyses, 1 RCT) with 2,043 total participants. Results are mixed across studies.

Key Study Findings

Case Reports n=1 6 weeks
Diagnosing Acute Kava Dermopathy: A Case Report of a Characteristic Cutaneous Eruption.
Dose: None vs: None Outcome: acute kava dermopathy with sebaceous gland necrosis Effet: None None

Population: 41-year-old Australian woman consuming kava for anxiety and insomnia

Case Reports n=1 Open-label
Severe kava withdrawal managed with phenobarbital.
Dose: None vs: None Outcome: Resolution of kava withdrawal symptoms Effet: None None

Population: 45-year-old man with kava and kratom withdrawal

Other Double-blind
The potential of AB-free kava in enabling tobacco cessation via management of abstinence-related stress and …
Dose: AB-free kava extract vs: Placebo Outcome: Tobacco cessation via stress/insomnia management Effet: None None

Population: Adult smokers (trial protocol)

Controlled Clinical Trial
Acute oral toxicity, antinociceptive and antimicrobial activities of kava dried extracts and synthetic kavain.
Dose: None vs: Vehicle control Outcome: Acute oral toxicity, antinociceptive activity Effet: None None

Population: Animal model

Systematic Review
The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review.
Dose: None vs: None Outcome: Sleep quality improvement Effet: None None

Population: Insomnia patients

Review
Calm Down With Kava: What Clinicians Need to Know.
Dose: None vs: None Outcome: None Effet: None None

Population: Kava users

Key Statistics

23

Études

2043

Participants

Mixed

A

Note

Referenced Papers

The American journal … 2025 1 citations
Journal of psychosocial … 2022 2 citations
Combinatorial chemistry & … 2021 16 citations
Chemical research in … 2019 6 citations
Journal of medicinal … 2018 19 citations
Sleep medicine reviews 2015 152 citations
Advances in pharmacological … 2011 79 citations
Integrative cancer therapies 2004 59 citations
Human psychopharmacology 2003 45 citations
Phytotherapy research : … 2001 74 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

sleep:
120-250 mg kavalactones/day, 1-2 hrs before bed

Limite supérieure : 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use

Posologies étudiées dans la recherche

Posologie Durée Effet N
None 6 weeks Negative 1
None -- Positive 1
AB-free kava extract -- Mixed --
None -- Positive --
None -- Mixed --
None -- Mixed --
None -- Mixed --
not specified -- Positive --

Moment optimal de prise : 1-2 hours before bed; avoid daily use beyond 3 months without medical supervision

Safety & Side Effects

Effets indésirables signalés

  • Drowsiness and reduced coordination
  • Hepatotoxicity (rare but serious — consult healthcare provider)
  • Skin rash (kava dermopathy) with chronic high-dose use
  • GI discomfort

Interactions connues

  • Alcohol — increased hepatotoxicity risk and CNS depression
  • Hepatotoxic medications (acetaminophen, statins) — additive liver stress
  • Benzodiazepines and sedatives — additive CNS depression
  • CYP450 substrates (2E1, 1A2, 2D6) — kavalactones may inhibit metabolism
  • Levodopa and dopaminergic drugs — kava may reduce efficacy

Apport maximal tolérable : 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does Kava help with Troubles du Sommeil Liés à l'Anxiété?
Based on 23 studies with 2,043 participants, there is strong evidence from multiple clinical trials that Kava may support Troubles du Sommeil Liés à l'Anxiété management. Our evidence grade is A (Strong Evidence).
How much Kava should I take for Troubles du Sommeil Liés à l'Anxiété?
Studies have used various dosages. A commonly studied range is 120-250 mg kavalactones/day, 1-2 hrs before bed. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Kava?
Reported side effects may include Drowsiness and reduced coordination, Hepatotoxicity (rare but serious — consult healthcare provider), Skin rash (kava dermopathy) with chronic high-dose use, GI discomfort. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Kava and Troubles du Sommeil Liés à l'Anxiété?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 23 peer-reviewed studies with 2,043 total participants. The overall direction of effect is mixed.

Related Evidence

Autres ingrédients pour Troubles du Sommeil Liés à l'Anxiété

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.